White Mountain Capital Reiterates Buy Rating on Nabi Biopharmaceuticals Ahead of Staphvax Data Release
05 10월 2005 - 7:05AM
PR Newswire (US)
NANUET, N.Y., Oct. 4 /PRNewswire/ -- Oren Levy, M.D., Ph.D.,
analyst for independent research provider White Mountain Capital,
LLC, reiterated his BUY rating on Nabi Biopharmaceuticals
(NasdaqNM: NABI) ahead of the release of Phase III trial data for
the Florida-based biotech company's lead candidate, StaphVAX.
"StaphVAX is the key determinant of Nabi's growth and development.
As such, the upcoming phase III data release is critical," Levy
said. "In our view, StaphVAX is a very promising late-stage
candidate because it targets a significant unmet medical need and
already has strong efficacy data from one phase III trial."
StaphVAX is a vaccine designed to elicit a protective immune
response against the most common strains of Staphylococcus aureus
("Staph"). Staph is a major cause of acquired infections in
chronically ill patients and is the most-commonly-isolated
bacterial pathogen in hospital-acquired infections. If approved,
StaphVAX would represent the first preventative approach to the
treatment of Staph. To obtain a copy of the report, call toll-free
866-833-5300 during market hours. About White Mountain Capital
White Mountain Capital is a full-service broker-dealer in New York.
Through its Biotechnology Research Department headed by Dr. Levy,
the firm issues independent research on select biotechnology
companies. Dr. Levy employs a proprietary research methodology
whereby ratings are based strongly on the viability and medical
necessity of companies' pipeline projects. CRD #104123. DISCLOSURE
INFORMATION The material in White Mountain Capital's reports is
based on data obtained from sources we deem to be reliable; it is
not guaranteed as to accuracy or completeness. More information or
supporting materials may be obtained by calling White Mountain
Capital toll-free at 866-833-5300. We certify that the evaluation
and opinions in this report are an accurate reflection of the
author's opinion about the company covered. The researcher who
prepared this report, and whose name appears on the front cover of
the report, certifies that the views expressed in the report
accurately reflect the author's personal views about the subject
company at the time of publication. White Mountain Capital's
researchers' compensation is not tied in any way to ratings issued
or stock performance of covered companies. Neither White Mountain
Capital nor the authoring analyst of any report was paid or given
any compensatory consideration by Nabi Biopharmaceuticals to issue
this report. White Mountain Capital, LLC initiated coverage on Nabi
Biopharmaceuticals on 08/07/02 with a BUY rating. White Mountain
Capital does not make a market in this stock. White Mountain
Capital has not participated in any investment banking activities
with subject company within the past 12 months, nor does it
anticipate participating or seeking participation in investment
banking activities within the next 3 months. No White Mountain
Capital employee or household members of any employee are a
director, officer or advisor of the covered company. White Mountain
Capital's affiliate, CLG Financial Corp, as well as two
non-director board members, have held long positions in the covered
company for more than one year. Neither White Mountain Capital nor
any of its affiliates beneficially own 1% or more of any class of
securities of the subject company. RATING DISCLOSURES (As of
10/04/05) RATING DEFINITION % OF COVERAGE BUY Outstanding company
with an appropriate 33% (4/12) valuation, or a company we feel is
significantly undervalued. HOLD Good company that is appropriately
valued 50% (6/12) or an outstanding company that is somewhat
overvalued. SELL Company that has significant weakness or 17%
(2/12) is significantly overvalued. White Mountain Capital has not
performed investment banking services for any of the companies
under coverage. DATASOURCE: White Mountain Capital, LLC CONTACT:
Stephen J. Callahan, Managing Director of Sales, +1-845-623-5959
x282, or Renee L. Luchkiw, Supervisor of Research, +1-845-623-5959
x284, both of White Mountain Capital, LLC Web site:
http://www.whitemountaincapital.com/
Copyright